38
Participants
Start Date
September 30, 2014
Primary Completion Date
November 6, 2021
Study Completion Date
November 6, 2021
Guanfacine
Participants will meet with the study doctor on a weekly basis during the treatment phase of the study. In the first few weeks, the daily dose of the medication will be individually adjusted by the study doctor according to participants' clinical response to and tolerability of the medication. The optimal dose will then be maintained for the remainder of the treatment period.
Lisdexamfetamine
Participants will meet with the study doctor on a weekly basis during the treatment phase of the study. In the first few weeks, the daily dose of the medication will be individually adjusted by the study doctor according to participants' clinical response to and tolerability of the medication. The optimal dose will then be maintained for the remainder of the treatment period.
New York State Psychiatric Institute, New York
Collaborators (1)
Columbia University
OTHER
American Academy of Child Adolescent Psychiatry.
OTHER
Shire
INDUSTRY
New York State Psychiatric Institute
OTHER